Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 73 to 77 of 77 entries
Sorted by: Best Match Show Resources per page
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.

Hepatology (Baltimore, Md.)

Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, Freilich BF, Younes ZH, Harlan W, Ghalib R, Oguchi G, Thuluvath PJ, Ortiz-Lasanta G, Rabinovitz M, Bernstein D, Bennett M, Hawkins T, Ravendhran N, Sheikh AM, Varunok P, Kowdley KV, Hennicken D, McPhee F, Rana K, Hughes EA.
PMID: 25614962
Hepatology. 2015 Apr;61(4):1127-35. doi: 10.1002/hep.27726. Epub 2015 Mar 10.

UNLABELLED: Treatment options for patients with hepatitis C virus (HCV) genotype 3 infection are limited, with the currently approved all-oral regimens requiring 24-week treatment and the addition of ribavirin (RBV). This phase III study (ALLY-3; ClinicalTrials.gov: NCT02032901) evaluated the...

Cite
Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015;61(4):1127-35doi: 10.1002/hep.27726.
Nelson, D. R., Cooper, J. N., Lalezari, J. P., Lawitz, E., Pockros, P. J., Gitlin, N., Freilich, B. F., Younes, Z. H., Harlan, W., Ghalib, R., Oguchi, G., Thuluvath, P. J., Ortiz-Lasanta, G., Rabinovitz, M., Bernstein, D., Bennett, M., Hawkins, T., Ravendhran, N., Sheikh, A. M., Varunok, P., Kowdley, K. V., Hennicken, D., McPhee, F., Rana, K., Hughes, E. A. (2015). All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology (Baltimore, Md.), 61(4), 1127-35. https://doi.org/10.1002/hep.27726
Nelson, David R, et al. "All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study." Hepatology (Baltimore, Md.) vol. 61,4 (2015): 1127-35. doi: https://doi.org/10.1002/hep.27726
Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, Freilich BF, Younes ZH, Harlan W, Ghalib R, Oguchi G, Thuluvath PJ, Ortiz-Lasanta G, Rabinovitz M, Bernstein D, Bennett M, Hawkins T, Ravendhran N, Sheikh AM, Varunok P, Kowdley KV, Hennicken D, McPhee F, Rana K, Hughes EA. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015 Apr;61(4):1127-35. doi: 10.1002/hep.27726. Epub 2015 Mar 10. PMID: 25614962; PMCID: PMC4409820.
Copy Download .nbib Format: NLM
A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection.

Journal of hepatology

Hassanein T, Sims KD, Bennett M, Gitlin N, Lawitz E, Nguyen T, Webster L, Younossi Z, Schwartz H, Thuluvath PJ, Zhou H, Rege B, McPhee F, Zhou N, Wind-Rotolo M, Chung E, Griffies A, Grasela DM, Gardiner DF.
PMID: 25559328
J Hepatol. 2015 May;62(5):1204-6. doi: 10.1016/j.jhep.2014.12.025. Epub 2015 Jan 02.

No abstract available.

Cite
Hassanein T, Sims KD, Bennett M, et al. A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection. J Hepatol. 2015;62(5):1204-6doi: 10.1016/j.jhep.2014.12.025.
Hassanein, T., Sims, K. D., Bennett, M., Gitlin, N., Lawitz, E., Nguyen, T., Webster, L., Younossi, Z., Schwartz, H., Thuluvath, P. J., Zhou, H., Rege, B., McPhee, F., Zhou, N., Wind-Rotolo, M., Chung, E., Griffies, A., Grasela, D. M., & Gardiner, D. F. (2015). A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection. Journal of hepatology, 62(5), 1204-6. https://doi.org/10.1016/j.jhep.2014.12.025
Hassanein, Tarek, et al. "A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection." Journal of hepatology vol. 62,5 (2015): 1204-6. doi: https://doi.org/10.1016/j.jhep.2014.12.025
Hassanein T, Sims KD, Bennett M, Gitlin N, Lawitz E, Nguyen T, Webster L, Younossi Z, Schwartz H, Thuluvath PJ, Zhou H, Rege B, McPhee F, Zhou N, Wind-Rotolo M, Chung E, Griffies A, Grasela DM, Gardiner DF. A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection. J Hepatol. 2015 May;62(5):1204-6. doi: 10.1016/j.jhep.2014.12.025. Epub 2015 Jan 02. PMID: 25559328.
Copy Download .nbib Format: NLM
Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients.

Liver international : official journal of the International Association for the Study of the Liver

Everson GT, Sims KD, Thuluvath PJ, Lawitz E, Hassanein T, Rodriguez-Torres M, Desta T, Hawkins T, Levin JM, Hinestrosa F, Rustgi V, Schwartz H, Younossi Z, Webster L, Gitlin N, Eley T, Huang SP, McPhee F, Grasela DM, Gardiner DF.
PMID: 26473667
Liver Int. 2016 Feb;36(2):189-97. doi: 10.1111/liv.12964. Epub 2015 Dec 06.

BACKGROUND AND AIMS: This phase-2b study examined the safety and efficacy of an all-oral, interferon-free combination of the NS5A replication complex inhibitor daclatasvir (DCV), the NS3 protease inhibitor asunaprevir (ASV), and the nonnucleoside NS5B polymerase inhibitor beclabuvir (BCV) with...

Cite
Everson GT, Sims KD, Thuluvath PJ, et al. Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients. Liver Int. 2015;36(2):189-97doi: 10.1111/liv.12964.
Everson, G. T., Sims, K. D., Thuluvath, P. J., Lawitz, E., Hassanein, T., Rodriguez-Torres, M., Desta, T., Hawkins, T., Levin, J. M., Hinestrosa, F., Rustgi, V., Schwartz, H., Younossi, Z., Webster, L., Gitlin, N., Eley, T., Huang, S. P., McPhee, F., Grasela, D. M., & Gardiner, D. F. (2016). Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients. Liver international : official journal of the International Association for the Study of the Liver, 36(2), 189-97. https://doi.org/10.1111/liv.12964
Everson, Gregory T, et al. "Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients." Liver international : official journal of the International Association for the Study of the Liver vol. 36,2 (2016): 189-97. doi: https://doi.org/10.1111/liv.12964
Everson GT, Sims KD, Thuluvath PJ, Lawitz E, Hassanein T, Rodriguez-Torres M, Desta T, Hawkins T, Levin JM, Hinestrosa F, Rustgi V, Schwartz H, Younossi Z, Webster L, Gitlin N, Eley T, Huang SP, McPhee F, Grasela DM, Gardiner DF. Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients. Liver Int. 2016 Feb;36(2):189-97. doi: 10.1111/liv.12964. Epub 2015 Dec 06. PMID: 26473667.
Copy Download .nbib Format: NLM
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.

The New England journal of medicine

Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Di Bisceglie AM, Arora S, Subramanian GM, Zhu Y, Dvory-Sobol H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Sulkowski M, Kwo P.
PMID: 24725238
N Engl J Med. 2014 Apr 17;370(16):1483-93. doi: 10.1056/NEJMoa1316366. Epub 2014 Apr 11.

BACKGROUND: Effective treatment for hepatitis C virus (HCV) genotype 1 infection in patients who have not had a sustained virologic response to prior interferon-based therapy represents an unmet medical need.METHODS: We conducted a phase 3, randomized, open-label study involving...

Cite
Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370(16):1483-93doi: 10.1056/NEJMoa1316366.
Afdhal, N., Reddy, K. R., Nelson, D. R., Lawitz, E., Gordon, S. C., Schiff, E., Nahass, R., Ghalib, R., Gitlin, N., Herring, R., Lalezari, J., Younes, Z. H., Pockros, P. J., Di Bisceglie, A. M., Arora, S., Subramanian, G. M., Zhu, Y., Dvory-Sobol, H., Yang, J. C., Pang, P. S., Symonds, W. T., McHutchison, J. G., Muir, A. J., Sulkowski, M., Kwo, P. (2014). Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. The New England journal of medicine, 370(16), 1483-93. https://doi.org/10.1056/NEJMoa1316366
Afdhal, Nezam, et al. "Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection." The New England journal of medicine vol. 370,16 (2014): 1483-93. doi: https://doi.org/10.1056/NEJMoa1316366
Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Di Bisceglie AM, Arora S, Subramanian GM, Zhu Y, Dvory-Sobol H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Sulkowski M, Kwo P. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014 Apr 17;370(16):1483-93. doi: 10.1056/NEJMoa1316366. Epub 2014 Apr 11. PMID: 24725238.
Copy Download .nbib Format: NLM
Acute hepatitis A: what's new with it?.

The American journal of gastroenterology

Chalasani N, Gitlin N.
PMID: 9820430
Am J Gastroenterol. 1998 Nov;93(11):2305-6. doi: 10.1111/j.1572-0241.1998.02305.x.

No abstract available.

Cite
Chalasani N, Gitlin N. Acute hepatitis A: what's new with it?. Am J Gastroenterol. 1998;93(11):2305-6doi: 10.1111/j.1572-0241.1998.02305.x.
Chalasani, N., & Gitlin, N. (1998). Acute hepatitis A: what's new with it?. The American journal of gastroenterology, 93(11), 2305-6. https://doi.org/10.1111/j.1572-0241.1998.02305.x
Chalasani, N, and Gitlin, N. "Acute hepatitis A: what's new with it?." The American journal of gastroenterology vol. 93,11 (1998): 2305-6. doi: https://doi.org/10.1111/j.1572-0241.1998.02305.x
Chalasani N, Gitlin N. Acute hepatitis A: what's new with it?. Am J Gastroenterol. 1998 Nov;93(11):2305-6. doi: 10.1111/j.1572-0241.1998.02305.x. PMID: 9820430.
Copy Download .nbib Format: NLM
Showing 73 to 77 of 77 entries